Overview

An Efficacy and Safety Study of DFN-02 (Sumatriptan Nasal Spray 10 mg)

Status:
Completed
Trial end date:
2017-02-10
Target enrollment:
Participant gender:
Summary
A safety and efficacy study of DFN-02 (Sumatriptan Nasal Spray 10 mg), being conducted at multiple centers in the United States.
Phase:
Phase 2
Details
Lead Sponsor:
Dr. Reddy's Laboratories Limited
Upsher-Smith Laboratories
Treatments:
Sumatriptan